Cerebrospinal fluid biomarkers of Alzheimer's disease.

Alzheimer's disease will reach epidemic proportions within the next 20-30 years if left unchecked. Currently, there are no treatments that prevent or slow Alzheimer's disease but many are being developed. Parallel efforts to develop biomarkers to aid in disease diagnosis and prognosis, and assess disease risk are currently underway. Clinicopathological and biomarker studies have demonstrated that Alzheimer's disease pathology can be detected preclinically. Using biomarkers to identify affected individuals prior to the onset of clinical symptoms and associated synaptic/neuronal loss should enable novel clinical trial design and early mechanism-based therapeutic intervention. This article summarizes the most promising cerebrospinal fluid biomarkers, highlights novel applications and current challenges, and provides a prediction on how the field may evolve in 5-10 years.

[1]  M. Sugishita,et al.  [Clinical Dementia Rating (CDR)]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[2]  Hilkka Soininen,et al.  J-ADNI and selection of cognition measures , 2010, Alzheimer's & Dementia.

[3]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[4]  Mark A Mintun,et al.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. , 2009, Archives of neurology.

[5]  A. Fagan,et al.  Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.

[6]  A. Fagan,et al.  Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.

[7]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[8]  Paolo Maria Rossini,et al.  Validation of Alzheimer’s disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI) , 2009, Experimental Gerontology.

[9]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[10]  Randall J Bateman,et al.  A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system , 2009, Annals of neurology.

[11]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[12]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[13]  A. Drzezga,et al.  Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid , 2009, Biological Psychiatry.

[14]  H. Soininen,et al.  Safety of lumbar puncture procedures in patients with Alzheimer's disease. , 2009, Current Alzheimer research.

[15]  A. Fagan,et al.  Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. , 2009, Archives of neurology.

[16]  F. Jessen,et al.  Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment , 2009, Dementia and Geriatric Cognitive Disorders.

[17]  A. Fagan,et al.  Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly , 2009, Annals of neurology.

[18]  A. Fagan,et al.  Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta , 2009, neurogenetics.

[19]  Johannes Kornhuber,et al.  Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease , 2009, Journal of Neural Transmission.

[20]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[21]  H. Soininen,et al.  PET Amyloid Ligand [11C]PIB Uptake and Cerebrospinal Fluid β-Amyloid in Mild Cognitive Impairment , 2008, Dementia and Geriatric Cognitive Disorders.

[22]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[23]  David L. Brody,et al.  Amyloid-β Dynamics Correlate with Neurological Status in the Injured Human Brain , 2008, Science.

[24]  Michael W. Weiner,et al.  The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium , 2008, Alzheimer's & Dementia.

[25]  A. Fagan,et al.  Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition , 2008, Proceedings of the National Academy of Sciences.

[26]  F. Jessen,et al.  Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study , 2008, Neurobiology of Aging.

[27]  K. Blennow,et al.  Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. , 2008, Brain : a journal of neurology.

[28]  F. Tortella,et al.  Detection of protein biomarkers using high-throughput immunoblotting following focal ischemic or penetrating ballistic-like brain injuries in rats , 2008, Brain injury.

[29]  M. J. Leon,et al.  Longitudinal CSF isoprostane and MRI atrophy in the progression to AD , 2007, Journal of Neurology.

[30]  David M Holtzman,et al.  Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease , 2007, Proteomics. Clinical applications.

[31]  I. Sokal,et al.  CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.

[32]  K. Blennow,et al.  Longitudinal stability of CSF biomarkers in Alzheimer's disease , 2007, Neuroscience Letters.

[33]  F. Jessen,et al.  Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho‐Tau in patients with low‐ and high‐CSF Aβ40 load , 2007 .

[34]  Henrik Zetterberg,et al.  Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.

[35]  P. Lewczuk,et al.  Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias , 2007, Molecular Psychiatry.

[36]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[37]  Norman Relkin,et al.  Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease , 2007, Annals of neurology.

[38]  K. Blennow,et al.  Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury , 2006, Neurology.

[39]  H. Soininen,et al.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.

[40]  P. Lewczuk,et al.  CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies , 2006, Journal of Neural Transmission.

[41]  J Philip Miller,et al.  Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI , 2006, Neurology.

[42]  Paul Edison,et al.  Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.

[43]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[44]  P. Lewczuk,et al.  CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia , 2006, Brain : a journal of neurology.

[45]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[46]  T. Beach,et al.  Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects , 2006, Neurological research.

[47]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[48]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[49]  Juan Manuel Maler,et al.  Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. , 2006, Clinical chemistry.

[50]  J. Morris,et al.  Antecedent Biomarkers of Alzheimer’s Disease: The Adult Children Study , 2005, Journal of geriatric psychiatry and neurology.

[51]  Norbert Schuff,et al.  Measurement of hippocampal subfields and age-related changes with high resolution MRI at 4tesla , 2005, Alzheimer's & Dementia.

[52]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[53]  Alan C. Evans,et al.  Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. , 2005, Archives of neurology.

[54]  C. Teel,et al.  Rural practitioners’ experiences in dementia diagnosis and treatment , 2004, Aging & mental health.

[55]  C. Beck,et al.  Overview of Alzheimer's disease. , 2004, The Nursing clinics of North America.

[56]  H. Möller,et al.  Core biological marker candidates of Alzheimer’s disease – perspectives for diagnosis, prediction of outcome and reflection of biological activity , 2004, Journal of Neural Transmission.

[57]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[58]  Juan Manuel Maler,et al.  Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau , 2004, Neurobiology of Aging.

[59]  K. Blennow,et al.  Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury , 2004, Neurology.

[60]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[61]  H. Ulmer,et al.  Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury , 2003, Neurology.

[62]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[63]  H. Arai,et al.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects , 2002, Neurology.

[64]  J. Kornhuber,et al.  Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.

[65]  J. Morris,et al.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.

[66]  M. J. Wade,et al.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. , 2001, Archives of neurology.

[67]  Katharina Buerger,et al.  Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease , 2001, Annals of neurology.

[68]  J. Price,et al.  Mild cognitive impairment represents early-stage Alzheimer disease. , 2001, Archives of neurology.

[69]  K. Yanagisawa,et al.  Age-Dependent Change in the Levels of Aβ40 and Aβ42 in Cerebrospinal Fluid from Control Subjects, and a Decrease in the Ratio of Aβ42 to Aβ40 Level in Cerebrospinal Fluid from Alzheimer’s Disease Patients , 2000, European Neurology.

[70]  D. Jeste,et al.  Alzheimer's disease and its management in the year 2010. , 1999, Psychiatric services.

[71]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[72]  M. Bobinski,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[73]  J. Morris,et al.  Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[74]  R. Mohs,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). , 1995, Neurology.

[75]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[76]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[77]  M. Albert,et al.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.

[78]  C. Filley.  Diagnosis of Alzheimer's disease. , 1988, Colorado medicine.

[79]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[80]  K. Blennow,et al.  Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. , 2007, Journal of Alzheimer's disease : JAD.

[81]  P. Lewczuk,et al.  CSF amyloid-b-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia , 2006 .

[82]  Charles D. Smith,et al.  Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.

[83]  R. Aebersold,et al.  Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. , 2005, Journal of Alzheimer's disease : JAD.

[84]  H. Wiśniewski,et al.  Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .

[85]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[86]  Levels of (cid:1) -Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment , 2022 .